Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Apr 24
Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…
06 Mar 24
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…
01 Mar 24
Abrysvo bivalent RSV vaccine showed 77.8% efficacy against RSV-associated LRTD after disease surveillance in season two, and 88.9%…
29 Feb 24
Agreement spans wide range of Medidata’s solutions to enhance clinical trial efficiency
27 Feb 24
Gepotidacin is a triazaacenaphthylene antibiotic that acts as a bactericidal agent by hindering bacterial DNA replication through a…
26 Feb 24
EmVenio's Community Research Site Network helps remove barriers for participation in clinical research for underrepresented communities
22 Feb 24
In the interim review of the Phase 3 LATITUDE study, performed by the Data Safety Monitoring Board (DSMB),…
15 Feb 24
The collaboration is focused on evaluating MEK inhibitor trametinib in combination with pan-RAF inhibitor naporafenib in SEACRAFT-1 and…
14 Feb 24
The Phase 2 KOURAGE trial will assess Auxora with associated acute hypoxemic respiratory failure in the first half…